<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03327961</url>
  </required_header>
  <id_info>
    <org_study_id>170899</org_study_id>
    <nct_id>NCT03327961</nct_id>
  </id_info>
  <brief_title>Scaffold in Emilia Romagna</brief_title>
  <acronym>SHERPA</acronym>
  <official_title>Scaffold Implantation in Emilia-Romagna</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of Ferrara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital of Ferrara</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prospective study will investigate the clinical performance and long-term safety of
      scaffold implantation in a real world regional setting
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronary stents are the default devices for the treatment of coronary artery disease in
      percutaneous coronary intervention (PCI) according to existing guidelines. However,
      thrombosis and restenosis are still the main limitations of current permanent metallic
      stents. In contrast to Bare Metal Stents (BMSs), Drug Eluting Stents (DESs) have a reduced
      restenosis rate due to the presence of antiproliferative agents in the coating layer of the
      stent surface and reduced rate of repeat revascularisation. However, late and very late stent
      thrombosis remains the limitation of DES in spite of prolonged dual antiplatelet
      therapy.Bioabsorbable scaffolds have been introduced to overcome limitations of permanent
      metallic stents.

      The aim of this observational prospective study is to investigate the clinical performance
      and long-term safety of scaffold in a real world regional setting.

      The investigators agreed in the following preferential/optimal indications:

        -  complete revascularization in patients with age &lt;65 years

        -  revascularization of long lesions (&gt;24 mm), especially located in left anterior
           descending

        -  spontaneous coronary dissection

      The investigators agreed in the following strategy implantation:

        -  mandatory predilatation

        -  sizing 1:1

        -  to avoid vessel with reference vessel diameter &lt;2.8 mm and &gt;3.8 mm

        -  to avoid vessel with severe calcifications

        -  mandatory postdilation with non compliant balloon &gt;0.5 the scaffold diameter
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2017</start_date>
  <completion_date type="Anticipated">November 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Device Oriented Cardiac Events</measure>
    <time_frame>1 year</time_frame>
    <description>cumulative occurence of cardiovascular death, target vessel myocardial infarction and target vessel revascularization. Target is defined the vessel treated with scaffold</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1111</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>scaffold</arm_group_label>
    <description>Patients receiving during PCI the implantation of at least one scaffold</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>scaffold</intervention_name>
    <description>implantation of scaffold (eg Magmaris, Desolve, Others)</description>
    <arm_group_label>scaffold</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with symptomatic coronary artery disease needing the treatment of de novo native
        coronary artery lesions.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subjects &gt;18 years

          -  sign of the patients informed consent

          -  implanation of at least one scaffold

        Exclusion Criteria:

          -  inability to garantuee at least one year follow-up

          -  inabiliuty to garantuee at least one year compliance to dual antiplatelet regimen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Veronica Lodolini</last_name>
    <phone>0532236450</phone>
    <phone_ext>+39</phone_ext>
    <email>veronica.lodolini@student.unife.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisa Mosele</last_name>
    <phone>0532236450</phone>
    <phone_ext>+39</phone_ext>
    <email>elisa21mosele@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Ferrara</name>
      <address>
        <city>Cona</city>
        <state>Ferrara</state>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Biscaglia, MD</last_name>
      <phone>+390532239883</phone>
      <email>bscsmn@unife.it</email>
    </contact>
    <investigator>
      <last_name>Gianluca Campo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matteo Tebaldi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlo Tumscitz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simone Biscaglia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Cardiologia, Ospedale Morgagni Pierantoni</name>
      <address>
        <city>Forlì</city>
        <state>Forlì-Cesena</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Tarantino, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maria Cecilia Hospital - GVM Care &amp; Research</name>
      <address>
        <city>Cotignola</city>
        <state>Ravenna</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Sbarzaglia, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria di Bologna</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Saia, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>U.O. Cardiologia, Ospedale Maggiore</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianni Casella, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>U.O. Cardiologia, Azienda Ospedaliera Universitaria di Modena, Policlinico</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Sgura</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>U.O. Cardiologia, Ospedale di Baggiovara</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniele Iaccarino, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>U.O. di Cardiologia, Azienda Ospedaliero-Universitaria di Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Menozzi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>U.O. di Cardiologia, Ospedale Santa Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Balduccelli, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>U.O. di Cardiologia, Ospedale degli Infermi</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Santarelli, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2017</study_first_submitted>
  <study_first_submitted_qc>October 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2017</study_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital of Ferrara</investigator_affiliation>
    <investigator_full_name>Gianluca Campo</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

